FDA approves new drug extension adaptation for Parkinson's disease

Parkinson's disease (PD) is an aggressive neurodegenerative disease caused by the gradual loss of brain cells that produce the neurotransmitter dopamine.
decline in dopamine in the brain leads to a wide range of motor and non-motor symptoms.
as the disease progresses, patients treated with L-Doba may re-emerge or suddenly regain stiffness, stiffness and tremors, known as the "shutdown period" between doses of the drug.
, over time, L-Doba can cause involuntary, uncontrolled movement, known as movement disorders.
and unpredictable transitions between seizures of motor disorders, normal movement and "off-period" episodes have had a considerable impact on a patient's life.
Gocovri re-release capsule is a non-competitive NMDA-subject antagonist that improves dopamine release and blocks dopamine re-absorption.
in 2017 it was approved by the FDA to treat movement disorders in patients with Parkinson's disease treated with lysopaedic dopa.
from two key, placebo-controlled Phase 3 clinical trials, Gocovri's treatment significantly reduced "off-period" time and movement disorders.
this leads to a clinically significant increase in the opening time of patients with Parkinson's disease who receive L-Doba-based medication.
, Gocovri showed sustained efficacy for at least two years in the open-label Phase 3 clinical trial EASE LID-2.
approval of Gocovri's second adaptive disorder is a major milestone for Parkinson's patients with motor complications in their daily lives.
is now the only drug approved for treatment of Parkinson's disease 'off period' and complications of movement disorders.
," said Neil F. McFarlane, Adamas' chief executive.
in 2021, we will work to improve Gocovri's access.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
: s1. Adamas Announces FDA Approval for Second Development for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson's Disease Patients Experiencing OFF Episodes. Retrieved February 1, 2021, from